Company Overview - Betters Medical Investment Holdings Limited, also known as Baird Medical, is a leading developer and provider of microwave ablation (MWA) medical devices in China, recently expanding into the U.S. market after receiving US FDA 510(k) clearances [1][6] - Baird Medical specializes in proprietary medical devices for treating benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps [6] Business Combination - Baird Medical has completed a business combination with ExcelFin Acquisition Corp, a publicly traded special purpose acquisition company, resulting in the formation of a new listed company, Baird Medical Investment Holdings Limited (PubCo) [1] - The shares and warrants of PubCo will begin trading on Nasdaq under the ticker symbols "BDMD" and "BDMDW" starting October 2, 2024 [1] Special Meeting and Approval - On September 26, 2024, ExcelFin held a special meeting where 91.36% of the voting capital stock was represented, with approximately 99.9% of votes cast in favor of the business combination [2] Financial Investment - Following the completion of the business combination, the founders of Baird Medical and Grand Fortune Capital, LLC, co-sponsor of ExcelFin, subscribed to a $4,900,000 Convertible Preferred investment in the company [3] Legal and Financial Advisors - Dechert LLP is serving as legal counsel to Baird Medical, while Allen Overy Shearman Sterling US LLP is legal counsel to ExcelFin [4] - Cohen & Company Capital Markets is the lead financial advisor to ExcelFin, along with EXOS Capital LLC, Roth Capital LLC, and Haitong International Securities (USA) Inc. [4] Regulatory Filings - The business combination was formalized through a Business Combination Agreement, with a registration statement filed with the SEC that includes a proxy statement and prospectus related to the transaction [5]

FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced that Baird Medical Investment Holdings Limited's ("PubCo") registration statement on Form F-4 (the "Registration Statement") related to their previously announced propos ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40933 ExcelFin Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2933776 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 86-2933776 (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 86-2933776 (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2022 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40933 ExcelFin Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2933776 (State ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) | Delaware | | 86-2933776 | | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State or other jurisdiction of incorporation or organization) Delaware 86-2933776 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40933 EXCELFIN ACQUISITION CORP. (Exac ...